In this study, we have identified the mechanism for the initiation of PGCCs and their role in generating therapeutic resistance: IL-6, a well-studied molecule in cancer biology and immunology, plays a critical role in the initiation of PGCCs and their communication with stromal reprogramming factors to acquire chemoresistance. This evidence concerns the gene IL6 and cancer.